TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2-12yrs,~* ASA Class I-II,~* Fasting,~* Unmedicated,~* Elective MRI scan~Exclusion Criteria:~* Cognitive impairment,~* On psychotropic medications,~* Taking multiple (\>2) antiepileptic medications,~* Requiring endotracheal intubation for GA

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane, propofol, Nasal oxygen (Type: ACTIVE_COMPARATOR): After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
- Sevoflurane, Propofol, LMA (Type: ACTIVE_COMPARATOR): After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
- Sevoflurane, sevoflurane, LMA (Type: ACTIVE_COMPARATOR): After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
- Sevoflurane, isoflurane, LMA (Type: ACTIVE_COMPARATOR): After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnancy~* undergoing a Cesarean delivery via a transverse incision at York Hospital labor and delivery~* Documented history of chronic opioid use or documented OUD, or currently utilizing medically assisted treatment (MAT)~Exclusion Criteria:~* Patients with a history of clinically significant cardiovascular, hepatic, or renal disease~* Non-English speaking~* Allergy to bupivacaine, lidocaine, zinc, silver or menthol~* Unable to consent, due to lack of decisional capacity or need for emergent Cesarean delivery~* History of glucose-6-phosphate deficiency~* Use of anti-arrhythmic drugs such as tocainide or mexiletine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Lidoderm patch (Type: ACTIVE_COMPARATOR): Participants will receive a topical 3.6% Lidocaine/1.25% Menthol patch at the time of their Cesarean section. Patches will be replaced every 12 hours for a total of 60 hours.
- Infusion pump (Type: ACTIVE_COMPARATOR): Participants will undergo placement of Ambu ACTion drug delivery system at the time of Cesarean delivery. 0.125% of bupivacaine will be infused at a rate of 8cc/hr for a total of 48-60hrs post-operatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced breast cancer diagnosed by guided core biopsy~* T \> 2 cm (any N), or any T and node positive (needle biopsy is required)~* Non-metastatic disease assessed by computed tomography and bone scintigraphy~* Histological grade 2 and Ki67 \> 15% or~* Histological grade 3 or~* Any triple negative (TN) or~* Inflammatory breast cancer (IBC)~* Normal left ventricular ejection fraction (LVEF)~* HER2-negative disease~Exclusion Criteria:~* Another malignancy within the last 5 years (except curatively treated skin carcinoma, in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular carcinoma of the breast)~* Clinically significant comorbidities as cardiovascular diseases, chronic obstructive pulmonary disease (COPD), renal or liver failure, psychiatric disorders~* LVEF value below institutional limits of normal~* Predominant lobular carcinoma histology~* Grade 1 tumors~* Detected or suspicious distant metastasis~* Neutrophils less than 1,500/µL, platelets less than 100,000/µL, hemoglobin less than 10 g/dL, AST more than 2.5x upper limit of normal (ULN), total bilirubin more than ULN, alkaline phosphatase more than 1.5x ULN~* Male sex~* HER2-positive breast cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel/doxorubicin/cyclophosphamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hepatocellular carcinoma with liver-dominant disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.~* The cancer is unresectable.~* All patients must be off all chemotherapeutic regimens for 30 days prior to and 30 days after TheraSphere treatment.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~* Age 18 years or older.~* Able to understand informed consent.~Exclusion Criteria:~* Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either:~  * single TheraSphere administration; or~ * cumulative delivery of radiation to the lungs greater than 50 Gy over multiple treatments.~* Evidence of any detectable Tc-99m macroaggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow.~* Previous radiation therapy to the lungs and/or to the upper abdomen~* Pregnancy~* Symptomatic lung disease.~* Significant extrahepatic disease representing an imminent life-threatening outcome.~* Active uncontrolled infection~* Any pre-treatment laboratory findings within 30 days of treatment demonstrating:~  * Aspartate or alanine aminotransferase level greater than 5 times upper normal limit.~ * Serum bilirubin greater than 2 mg/dl~ * Infiltrative tumor on imaging~ * Tumor volume greater than 70% of liver volume~ * Tumor volume greater than 50% of liver volume and serum albumin level less than 3 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yttrium-90 liver radioembolization (Type: EXPERIMENTAL): Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Self-report a diagnosis of Hepatitis C~* English speaking individuals~* 18 years or older~* Must have access to an iPhone that operates on iOS version 8 or higher~* Be able to download apps from the U.S. Apple iPhone Store, and enter data themselves or via a proxy on their behalf~Exclusion Criteria:~• Individuals not meeting inclusion criteria will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:3.1.1 Patients with suspected or biopsy-proven liver masses including unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment.~3.1.2 Patients who have undergone prior chemotherapy more than one year prior to the study are eligible for enrollment.~3.1.4 Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.~3.1.5 No life expectancy restrictions.~3.1.6 ECOG and Karnofsky Performance Status will not be employed.~3.1.7 Patients with renal failure are ineligible for this study (Glomerular filtration rate (GFR) must be \> 60)~3.1.8 Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria:3.2.1 Patients who have undergone prior chemoembolization of hepatocellular carcinoma (HCC) are ineligible for enrollment. Patients who have undergone chemotherapy within one year prior to the study are also ineligible for enrollment.~3.2.2 No restrictions regarding use of other investigational agents.~3.2.3 Patients with severe contrast allergy are ineligible.~3.2.4 Patients who are pregnant or are trying to become pregnant are excluded from this study.~3.2.5 Patients who are cancer survivors or Human Immunodeficiency Virus (HIV)-positive will not be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- neuroendocrine metastases (Type: None): 15 patients with neuroendocrine metastases
- colon cancer metastases (Type: None): 15 patients with colon cancer metastases
- HCC treated with cyberknife radiation and chemotherapy (Type: None): 15 patients with HCC treated with cyberknife radiation and chemotherapy
- HCC treated with Sirsphere embolization and chemotherapy (Type: None): 15 patients with HCC treated with Sirsphere embolization and chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Modalities for Pancreatic Collections

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients who are known to have a pancreatic fluid collection after an episode of acute pancreatitis~* age greater than 18 years~Exclusion Criteria:~* pregnant woman~* age \<18 years~* prisoners~* other institutionalized individuals~* patients who are decisionally impaired

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Complications Related to Arthroscopic Surgery of the Hip - a Prospective Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing hip arthroscopic surgery at Horsens Hospital, Denmark, during one year.~Exclusion Criteria:~* Non

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients (Type: None): Patients having Hip arthroscopic surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection, requiring allogeneic, haematopoietic SCT as determined by their treating Physician (Haematologist).~* Over 18 years of age~* Provision of written, informed consent~Exclusion Criteria:~* In the opinion of the investigator that the patient is not able to provide informed consent~* Hb \< 9 (g/dL)~* CD4+ T cell count \<100 (cells/µl)~* Serious coagulation abnormalities, platelet count \< 50.~* Patients currently taking medications that significantly affect the bleeding time (e.g. warfarine, clexane, FXa antagonists)~* History of allergy to local anaesthetics~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior signed written informed from family member (no more needed following amendment in July 2016)~* 16 years of age or older~* Brain death diagnosis~* Left ventricular ejection fraction \< 50% determined by transthoracic echocardiography or hemodynamic instability defined as a mean dose of noradrenaline 0.1 mcg/kg/min + vasopressin~Exclusion Criteria:~* Heart failure history (removed after june 2015)~* Chronic exogenous oral T4 or T3 before death (removed after june 2015)~* Having received T4 infusion before recruitment(removed after june 2015)~* Echographic images not interpretable~  * Age 75 and older(removed after june 2015)~ * Prior coronary heart disease defined as prior coronary artery bypass graft or percutaneous coronary intervention (with or without stents)(removed after june 2015)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levothyroxine (Type: ACTIVE_COMPARATOR): Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
- Placebo (Type: PLACEBO_COMPARATOR): Infusion matched to intervention arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key inclusion criteria:~* Patient was diagnosed with multiple myeloma based on standard IMWG criteria~* Prior treatment with ≥ 2 treatment lines of anti-myeloma therapy~* Patients must have been exposed to both lenalidomide and bortezomib~* Measurable disease for myeloma defined as one of the following: serum M-protein ≥ 5 g/L; urine M-protein ≥ 0.2 g/24 hours~* Refractory or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last myeloma therapy.~* Adequate hematological and hepatic function~* A negative pregnancy test before inclusion into the trial is required for all women with child-bearing potential~Key exclusion criteria:~* History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration, with the exception of pT1-2 prostate cancer Gleason score ≤6, adequately treated, cervical carcinoma in situ or localized non-melanoma skin cancer.~* Polyneuropathy grade \> 2~* Patients who received any of the following within the last 14 days of initiation of trial treatment:~  * Plasmapheresis~ * Major surgery (kyphoplasty is not considered major surgery)~ * Radiation therapy~ * Use of any anti-myeloma drug therapy~* Known or clinically suspected myeloma manifestations in the central nervous system~* Severe or uncontrolled cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pomalidomide (Type: EXPERIMENTAL): The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from a manic or mixed episode.~Exclusion Criteria:~* Patients who have not provided personal informed consent,~* Known intolerance, hypersensitivity or lack of antimanic response to sodium valproate or quetiapine fumarate,~* Involuntary admittance/detainment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): quetiapine fumarate monotherapy
- 2 (Type: EXPERIMENTAL): Quetiapine + sodium valproate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed high-grade glioma (WHO grade III or IV)~* Must be scheduled to receive standard first-line therapy (cranial radiotherapy and temozolomide)~PATIENT CHARACTERISTICS:~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.7 mg/dL~* Bilirubin ≤ 1.5 mg/dL~* Transaminases ≤ 4 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell carcinoma of the skin~PRIOR CONCURRENT THERAPY:~* No prior hormonal therapy for brain tumor~* No prior biological agents (including immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy)~* No prior immunotherapy~* No prior chemotherapy~* No prior radiotherapy, including cranial radiotherapy~* Concurrent glucocorticoid therapy allowed~* No concurrent carbamazepine~* No other concurrent experimental therapy~* No other concurrent cytotoxic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues